S
Shanghai Yiru Biotechnology
Biotech & Life Sciences · China · Founded 2021
Sustainable biomaterials developed via synthetic biology methods MoreLess
Shanghai Yiru Biotechnology Co., Ltd., operating as SynMetabio, was founded in 2021 and is headquartered in Shanghai, China. The company develops next-generation sustainable biomaterials by integrating biotechnology with materials modification science. SynMetabio leverages synthetic biology, including gene editing and precision fermentation, to create novel bio-based materials from recycled biomass waste like discarded fruit and straw. These materials are designed to offer unique visual textures, scents, and tactile qualities.
The company's product line includes bio-based leather, mycelium-based materials, and other biomaterials. These products serve a wide range of industries, including fashion, furniture, and automotive. For example, the firm has developed a bio-based leather called Naro and has partnered with Anta to create sneakers from mycelium material. In a collaboration with Dole, SynMetabio is converting waste fruit into 100% bio-based materials using mycelium.
The company was founded by Su Rui, who, as an undergraduate at ShanghaiTech University, developed an interest in the intersection of biology and materials science. SynMetabio has received funding from investors such as Miracleplus, Linear Capital, Danen Capital, and K2VC. With a research and development center of nearly 2,000 square meters, the company has established a platform for the development and pilot production of microbial fiber materials.
Keywords: synthetic biology, biomaterials, sustainable materials, precision fermentation, mycelium, bio-based leather, material innovation, circular economy, biotech, cleantech, material science, biomass waste recycling, sustainable fashion, alternative materials, biofabrication, bioplastics, gene editing, microbial materials, protein design, green technology
Valuation & funding
Shanghai Yiru Biotechnology funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2026 | $14M | $55M | Chaosheng Capital · Hedera Finances · Ordos Group | ↗ |
| SEED✓Equity / VC | Apr 2024 | $2.8M | $14M | MiraclePlus · Star Capital · Linear · Danen Capital | ↗ |
| SEED✓Equity / VC | Mar 2023 | $2.8M | $11M | K2VC · Linear Capital · MiraclePlus · Danen Capital | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 2 |
| 2025 | 2 |
| 2024 | 2 |
Growth signals
Shanghai Yiru Biotechnology website traffic
Latest recorded traffic for Shanghai Yiru Biotechnology is 80 monthly website visits, down 87.9% over the last three months. Shanghai Yiru Biotechnology's team grew 0% over the past year.
Comparisons
Shanghai Yiru Biotechnology compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Shanghai Yiru Biotechnology's talent
Source: Dealroom Talent Intelligence.
Investors
9 investors on Shanghai Yiru Biotechnology's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Shanghai Yiru Biotechnology has talent and traffic
In the news
Latest news about Shanghai Yiru Biotechnology
Recent press, funding announcements, and product moves mentioning Shanghai Yiru Biotechnology — open to read from the original sources.
Market sentiment
What the market is saying about Shanghai Yiru Biotechnology
An AI-synthesized read of the highest-engagement posts about Shanghai Yiru Biotechnology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Yiru Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.












